Cinqair (Reslizumab) for asthma | MyAsthmaTeam

Connect with others who understand.

sign up log in
About MyAsthmaTeam
Powered By

Cinqair is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat severe asthma in people 18 years of age and older. Cinqair is also referred to by its drug name, reslizumab.

Cinqair is a member of a class of drugs called monoclonal antibodies. Cinqair is believed to work by binding to a proinflammatory cytokine (chemical messenger) known as IL-5. This binding prevents the maturation of eosinophils, which are white blood cells that release leukotrienes. Leukotrienes are chemicals involved in airway edema (swelling), smooth muscle contraction, and other processes associated with the symptoms of asthma. Inhibiting (holding back) their release helps to relieve these symptoms.

How do I take it?
Prescribing information states that Cinqair is given as an intravenous (into your vein) injection by a health care professional. Cinqair is usually given in a health clinic or doctor’s office once every four weeks. It should be administered according to the frequency specified by the physician.

Cinqair is available only as an intravenous injection.

Side effects
The FDA-approved label for Cinqair lists common side effects including sore throat.

Rare but serious side effects listed for Cinqair include increased risk for certain types of cancer and parasitic infection.

For more details about this treatment, visit:

Cinqair — Teva Support Solutions

Reslizumab (Intravenous Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in